About this course

Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side-effect with severe impact on patients’ quality of life. Despite recently updated antiemesis guidelines, CINV control is suboptimal, with poor patient adherence rates affecting overall outcomes. In this e-learning module, we discuss the importance of CINV management considering risk factors and antiemetic potential of chemotherapy agents. Latest evidence on the potential of dual-pathway targeted therapies will be discussed, along with strategies to overcome specific barriers to treatment.

Learning outcomes

• Understand the clinical unmet needs in CINV and importance of controlling both acute and delayed CINV from the start of chemotherapy
• Evaluate risk factors for CINV and current guideline recommendations on a risk-based approach to CINV management
• Discuss the data on antiemetic therapies and realise the clinical benefits of dual-pathway targeted CINV treatments
• Close the perception gap of the incidence and severity of patients’ CINV symptoms in relation to their reported outcomes

Topics covered

• CINV: Overview and clinical unmet needs
• Treatment goals and current management of CINV
• Risk factors of CINV
• Clinical benefits of combination treatment
• Overcoming barriers in CINV control
• Summary and key takeaways

Sponsored by